Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 5Completed 3Withdrawn 1Unknown 1Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 31Breast 25Thoracic 16Lymphoid 5Genitourinary 5Tumor-Agnostic 4Sarcoma 4Head & Neck 4Gynecologic 4Plasma cell 3Dermatologic 2Other solid neoplasm 1Other neoplasm 1Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Advanced Solid Tumor 1

Interventions

pembrolizumab 26Cisplatin 15Pemetrexed 14Paclitaxel 14Carboplatin 14Nivolumab 10Cyclophosphamide 10Docetaxel 8atezolizumab 7Injections 7Melphalan 6tislelizumab 5olaparib 5Gemcitabine 5Filgrastim 5durvalumab 4aldesleukin 4Leucovorin 4Irinotecan 4Granulocyte Colony-Stimulating Factor 4Etoposide 4Bevacizumab 4tocilizumab 3spartalizumab 3liposomal doxorubicin 3ixabepilone 3fludarabine 3epacadostat 3defactinib 3adavosertib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Albumin-Bound Paclitaxel × Other solid neoplasm × Clear all
NCT04761601 2024-03-13

First in Human Study of UCT-01-097 in Participants With Advanced Solid Tumors

1200 Pharma, LLC

Phase 1 Terminated
32 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡